TARGET THERAPY FOR DISSEMINATED CANCER OF THE CERVIX UTERI
https://doi.org/10.17650/1994-4098-2009-0-3-4-125-129
Abstract
The paper gives recent data on the use of target agents, such as erlotinib, gefitinib, cetuximab, bevacizumab, and sorafinib in advanced cancer of the cervix uteri (CCI). Approaches using target drugs in combination with chemotherapy are of the greatest interest. A spec- trum of molecular biomarkers (epidermal and vascular growth factors) in CCI and its correlation with prognosis and treatment response are shown. A number of adverse relations caused by target agents are considered.
About the Authors
V. A. Gorbunova
Department of Chemotherapy, N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
A. v Odintsova
Department of Chemotherapy, N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
S. V. Khokhlova
Department of Chemotherapy, N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
References
1. Давыдов М., Аксель Е. Статистика злокачественных новообразований в России и странах СНГ в 2004 г. М., 2006.
2. Ременник Л.В., Новикова Е.Г., Мокина В.Д. и др. Злокачественные новообразования женских половых органов. Рос онкол журн 1997;(6):4—8.
3. Gaffney D.K., Haslam D., Tsodikov A. et al. Epidermal growth fac- tor receptor (EGFR) and vascular endothelial growth factor (VEGF) nega- tively affect overall survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 2003;56(4):922—8.
4. Perez-Regadera J. et al. Impact of epi- dermal growth factor (EGFR) expression in desease free survival and rate of pelvic recurrences in advanced cervix cancer patients treated with chemoradiotherapy. ECCO, 2005;13:abstr. 925.
5. Randall-Whitis L., Monk B.J., Han E.S. et al. Markers of angiogenesis in cervical cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007, ASCO Annual Meeting Proceedings;25(18S):5536.
6. Ramondetta et al. Gyn Onc 2003, P.259-536
7. Mitsuhashi A., Suzuka K., Seki K. et al. Serum vaskular endothelial growth factor (VEGF) and VEGF-c levels as tumor markers in patients with cervical cancer. J Clin Oncol 2005;ASCO Annual Meeting Proceedings;23(16S):5075.
8. Ferreira C.G., Salgado M., Lima R. et al. A phase I trial of erlotinib (E), cis- platin (C) and radiotherapy (RT) for patients with locally advanced squamosus cell cervical cancer. ASCO, 2006; abstr. 13081.
9. Ferreira C.G. et al. Journal of Clinical Oncology 26,2008 ASCO (May 20 Supplement),abstr:5511
10. Goncalves A. et al Institut Paoli Calmettes Gynecol Oncol 2008 Jan;108(1):42-6.Epub 2007 Nov 5.
11. Kurtz E. et al. J Clin Oncol 26:2008 May 20 suppl; 5512
12. Wright J.D. et al. Journal of Clinical Oncology 2006 Nov;103(2):489-93.Epub 2006 May 2.
13. Nimeiri H.S., Oza A.M., Mergan R.J. et al. Sorafenib in patients with advanced uterine carcinoma or carcinosarcoma: a phase II trial of the University of Chicago, PMH, and California Phase II Consortia. J Clin Oncol 2008;26:abstr 5585.
Review
For citations:
Gorbunova V.A., Odintsova A.v., Khokhlova S.V. TARGET THERAPY FOR DISSEMINATED CANCER OF THE CERVIX UTERI. Tumors of female reproductive system. 2009;(3-4):125-129. (In Russ.) https://doi.org/10.17650/1994-4098-2009-0-3-4-125-129
Views:
1145
Email this article 